Department of General Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawacho Nishinomiyashi Hyogo 663-8501, Japan.
Lung Cancer. 2010 Jun;68(3):498-500. doi: 10.1016/j.lungcan.2010.02.008. Epub 2010 Mar 21.
The diagnosis of multiple primary lung cancer is sometimes difficult when multiple lung tumors with the same histologic type are identified. We now present a case of synchronous double primary lung adenocarcinomas (one in the right upper lobe and another in the right middle lobe) diagnosed based on mutational analysis of the epidermal growth factor receptor (EGFR) gene, although clinico-pathological findings suggested the diagnosis of intrapulmonary metastasis. After complete resection, pathological sections revealed the similar pathological features of two adenocarcinomas and unexpected subcarinal nodal metastasis. As the L858R mutation within exon 21 of the EGFR gene was identified in the middle-lobe tumor and the subcarinal node but not in the upper-lobe tumor, we diagnosed as double primary cancers. Local mediastinal recurrence after operation has been well-controlled with administration of gefitinib, a EGFR-tyrosine kinase inhibitor, and mutational analysis of the EGFR gene provided important information not only in the diagnosis of double primary cancers but also in decision-making of selection of chemotherapeutic agent.
当多个具有相同组织学类型的肺肿瘤被识别时,有时难以诊断多原发肺癌。我们现在报告一例同步双原发性肺腺癌(右上叶和右中叶各一例)的病例,该病例基于表皮生长因子受体(EGFR)基因突变分析诊断,尽管临床病理检查结果提示肺内转移的诊断。完全切除后,病理切片显示两个腺癌具有相似的病理特征和意外的隆突下淋巴结转移。由于在中叶肿瘤和隆突下淋巴结中发现了 EGFR 基因外显子 21 中的 L858R 突变,但在上叶肿瘤中未发现,因此我们诊断为双原发性癌。手术后局部纵隔复发,使用表皮生长因子受体酪氨酸激酶抑制剂吉非替尼得到很好的控制,EGFR 基因突变分析不仅为双原发性癌的诊断提供了重要信息,而且为选择化疗药物的决策提供了重要信息。